Abstract:Abstract Breast cancer is the most common cancer among women. Of all breast cancers cases, approximately 30% have amplifications of the self-antigen HER2/neu. Later studies have also found antibody response and T cell response specific for HER2/neu in cancer patients, indicating HER2/neu may be a good target for active immunotherapy. Following studies on HER2/neu targeted immunotherapeutic strategies all have been proven to be incapable of breaking tolerance towards HER2/neu, and couldn't elicit adequate antitumor immunity in curing HER2/neu positive breast cancer in spontaneously developed tumor transgenic mouse model, although both humeral and cellular immune responses could be detected. CD4+ T helper cells play an essential role in antitumor immunity. Reports have demonstrated that CD8+ T cells at resting or non-responsive state can be activated by providing cytokines and co-stimulatory signals, suggesting T cell help activation is crucial in breaking CD8+ CTL tolerance. The tetanus toxoid Th P30 has been found to be a universal and potent epitope in sensitizing and proliferating CD4+ T cells ex vivo. In this study, to evaluate the P30 effect on vaccine efficacy, we constructed two recombinant AdVs (AdVOVA-P30 and AdVHER2/neu-P30) expressing ovalbumin (OVA)-P30 and HER2/neu-P30, and two AdV transduced DC vaccines (DCOVA-P30 and DCHER2/neu-P30), and then compared the the immunization efficacy between vaccines with and without Th epitope P30 in the same vaccine modality in wild-type C57BL6 mouse model, a mouse model for OVA/OVA-P30 system study, and FVNneuN mouse model, a in vivo murine tumor model expressing the rat neu Ag. We demonstrate that both AdVOVA and AdVOVA-P30 vaccines could stimulate super high level of OVA-specific CD8+ T lymphocytes (CTLs) in wild-type C56BL/6 mice, but with no significant defference. However, when assess the immune responses induced by DCOVA and DCOVA-P30, we found both of CD4+ T cell and OVA-sepcific CD8+ T cell responses induced by DCOVA-P30 are significantly higher than that of DCOVA. Futher study on in vivo cytotoxic assay also confirmed this finding. Althogh both of DCOVA and DCOVA-P30 vaccines could lead to preventive long-term immunity against OVA-expressing BL6-10OVA melanoma in metastasizing in wild-type C56BL/6 mice, therapeutic antitumor immunity induced by DCOVA-P30 vaccine could kill significantly higher amount of pre-existing BL6-10OVA melanoma, suggesting that with the help of the universal potent Th epitope P30, vaccine efficacy could be enhanced. When apply such vaccine modality to HER2/neu-tolerance mouse model FVNneuN so as to enhace the anti-HER2/neu immunity, we also found DCneu-P30 could stimulate stronger CD8+ T cell response that of DCHER2/neu, leading to signigicantly stronger preventive antitumor immunity against HER2/neu expressing tumor cell line from FVNneuN, prolonging the life span of FVNneuN mice. Citation Format: Yuxiu Chen, Yufeng Xie, Jim Xiang. Potent Th cell epitope modified HER2/neu dendritc cell vaccine magnify antitumor responses in HER2/neu tolerance transgenic mice. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr A26.

A Single Low Dose of Dendritic Cells Modified with Lentivirus Containing a Truncated Neu Gene Can Effectively Suppress Neu-Overexpressing Tumors.

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination

DC Targeting DNA Vaccines Induce Protective and Therapeutic Antitumor Immunity in Mice.

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer

Adjuvant Effect of HER-2/neu-specific Adenoviral Vector Stimulating CD8⁺ T and Natural Killer Cell Responses on Anti-Her-2/neu Antibody Therapy for Well-Established Breast Tumors in HER-2/neu Transgenic Mice.

P3.02c-049 Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect Against Lung Cancer

Abstract A26: Potent Th Cell Epitope Modified HER2/neu Dendritc Cell Vaccine Magnify Antitumor Responses in HER2/neu Tolerance Transgenic Mice.

[Immunostimulatory effect of human peripheral blood dendritic cells transfected by adeno-associated virus containing Her2/neu gene].

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Co-transfection Gene Delivery of Dendritic Cells Induced Effective Lymph Node Targeting and Anti-tumor Vaccination

Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu

Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses

Immunoediting breast cancer using HER-2/neu pulsed autologous dendritic cell vaccines

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion

[Antitumor Effect of Gene Gun-Mediated DNA Vaccine Pwrg-Neu Immunization in C57BL/6 Mice].

Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response

[Controlled Live Dendritic Cell Vaccine Mediates Potent Antitumor Immune Responses].